U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06841094) titled 'Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy' on Feb. 20.
Brief Summary: The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).
Study Start Date: July 20, 2023
Study Type: INTERVENTIONAL
Condition:
IgA Nephropathy
Immunoglobulin A Nephropathy
Intervention:
DRUG: Atrasentan
Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - ...